

Review of: "13 cis retinoic acid improved the outcomes of COVID-19 patients. A randomized clinical trial"

Paulo Santos¹

¹ Universidade de São Paulo

Potential competing interests: The author(s) declared that no potential competing interests exist.

The paper is about 13 cis retinoic acid to improved the treatment to COVID-19 patients. A randomized study.

The study is interesting and promising. But, there are some considerations to be made:

1. The introduction is too long and the literature review conducted does not justify the study. I suggest that there is more information on the choice of 13 cis retinoic acid acting on SARS-CoV2 to justify the study and explain the choice of this drug for this use properly.
2. I could not find in the methodology of the study the exclusion criteria, even though in the limitations at the end of the article it was mentioned that pregnant women were excluded.
3. The time after the onset of symptoms is directly related to the amount of virus in the oropharynx and oral cavity. In the methodology, it is necessary to state how long after the onset of symptoms treatment with 13 cis retinoic acid was started.
4. I could not identify which forms of presentation of the drug 13 cis retinoic acid were given in the survey. Was it an inhalation presentation and another in mouth rinses or oral ingestion for systemic action? I think it is important to clarify this data.
5. The results are interesting and well presented.
6. The conclusions cannot be so affirmative in view of the limitation of the sample in the study conducted. I think it is better to conclude by stating that the use of 13 cis retinoic acid is a promising adjuvant therapy option.
7. References do not have a standard presentation, so they must be adjusted. Preferably in Vancouver format.